SINT Stock Forecast & Price Target

SINTX Technologies is building a more commercial, higher-upside orthopedic and biomaterials business through its silicon nitride platform, with the June 2025 acquisition of SiNAPTIC adding six differentiated foot and ankle implant systems and expanding its addressable market. The October 2025 FDA 510(k) clearance, December 2025 Evonik manufacturing agreement, and March 2026 first-in-human procedure provide clear validation of product readiness, clinical traction, and partnership momentum. Financially, 1Q26 revenue of $0.38M grew 3% y/y, while continuing operations rose 46% and product revenue increased 32%, suggesting early commercialization progress despite the still-small revenue base and significant upside potential.

SINTX Technologies is challenged by weak profitability and fragile liquidity, as Q2 2026 revenue was only $0.5 million while net loss widened to $3.6 million, or $(0.75) per share, with no Q2 guidance provided. The company’s outlook is further pressured by the need for surgeon adoption, commercialization execution, regulatory approvals, reimbursement, and partnership development, all of which remain uncertain and capital intensive. With balance sheet risk and explicit going-concern risk cited alongside competitive pressure and dependence on future pipeline success, the fundamental case remains highly speculative.